Expression of Interleukin-10 and Interleukin-15 in Patients with Multiple Myeloma and Its Clinical Significance.
10.19746/j.cnki.issn.1009-2137.2025.03.030
- Author:
Xiao-Dong ZHANG
1
;
Meng LI
1
;
Hai-Xia LIU
1
;
Dan-Feng ZHANG
2
Author Information
1. Department of Hematology, Nanyang First People's Hospital, Nanyang 473012, Henan Province, China.
2. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China.
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
interleukin-10;
interleukin-15;
prognosis
- MeSH:
Humans;
Interleukin-10/metabolism*;
Multiple Myeloma/metabolism*;
Interleukin-15/metabolism*;
Prognosis;
Female;
Male;
Middle Aged;
Clinical Relevance
- From:
Journal of Experimental Hematology
2025;33(3):828-833
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression and clinical significance of interleukin-10 (IL-10) and interleukin-15 (IL-15) in patients with multiple myeloma (MM).
METHODS:Eighty newly diagnosed MM patients in Department of Hematology in Nanyang First People's Hospital from September 2020 to January 2023 were selected as observation group, and 80 healthy people in our hospital were selected as control group. The expression of IL-10 and IL-15 of the two groups were detected, and survival analysis was conducted for the MM patients.
RESULTS:The levels of IL-10 and IL-15 in the observation group before treatment were significantly higher than those in the control group (both P <0.05). The levels of IL-10 and IL-15 in different DS stage had significant differences in MM patients (both P <0.05). The levels of IL-10 and IL-15 in stage II and stage III had no significant differences, which were both significantly higher than those in stage I (both P <0.05). The levels of IL-10 and IL-15 in sCR+CR group after treatment were significantly lower than those before treatment (both P <0.05). The levels of IL-10 and IL-15 in VGPR+PR group after treatment were also significantly lower than those before treatment (both P <0.05), but higher than those in the sCR+CR group (both P <0.05). The progression-free survival (PFS) and overall survival (OS) of patients with IL-10>22.01 pg/ml were significantly shorter than those with IL-10≤22.01 pg/ml (both P <0.001). The PFS and OS of patients with IL-15>48.56 pg/ml were also shorter than those with IL-15≤48.56 pg/ml (both P <0.05).
CONCLUSIONS:The levels of IL-10 and IL-15 in MM patients are closely related to efficacy and prognosis, and both decreased after treatment. The more reduction, the better effect. Patients with IL-10 and IL-15 below the threshold have longer median PFS and OS.
